Commitment to Research

Since 1996 Erchonia, the manufacturer of ZERONA has been committed to fully elucidating the medical utility of low-level laser therapy through rigorous clinical studies. ZERONA has been examined extensively from in vitro and ex-vivo analyses to in vivo clinical investigations.

Presently, Erchonia remains steadfast to unlocking the potential benefits of ZERONA by exploring subtle changes within adipocyte function that could modulate DNA expression, protein and hormone synthesis, ultimately affecting the endocrine and immune systems. As you will quickly learn, ZERONA was built on a solid foundation of histological and clinical evidence and should reassure you and your clinic that ZERONA will provide patients with a reliable, safe, and effective non-invasive contouring of the waist, hips, and thighs.

Erchonia has developed other products that are designed and FDA cleared for use during liposuction and breast augmentation. This lead to the non-invasive ZERONA laser which emulsifies the adipose tissue and releases excess fat into the interstitial space. From there, fat is passed through the body during its normal course of detoxification.
Following the ZERONA protocol, physicians can be confident they are treating their patients with the safest and most researched low level laser in the world.

DID YOU KNOW?
ZERONA is the only device
available that does not harm
or kill the fat cell.